Economic and epidemiological impact of dengue illness over 16 years from a public health system perspective in Brazil to inform future health policies including the adoption of a dengue vaccine by Godói, Isabella Piassi et al.
1 
 
Economic and Epidemiological Impact of Dengue in Brazil (2000-2015) from a public health 
system perspective: Implications of adopting of a dengue vaccine  
 
Isabella Piassi Godóia,b; Leonardo Vinicius Dias da Silvab,c; Abdur Razzaque Sarkerd,e; Itamar 
Megiddoe,f; Alec Mortone; Brian Godmang,h,i.j; Samantha Alvarez-Madrazog,k,; Marion Bennieh; Augusto 
Afonso Guerra Juniora,b  
 
aPrograma de Pós-graduação em Medicamentos e Assistência Farmacêutica, sala 1023, Faculdade 
de Farmácia, Universidade Federal de Minas Gerais, Av. Presidente Antônio Carlos, 6627, Campus 
Pampulha, Belo Horizonte, Minas Gerais, CEP 31270-901, Brazil. Email: isabellapiassi@gmail.com;  
augustoguerramg@gmail.com 
bSUS Collaborating Centre for Technology Assessment and Excellence in Health, sala 1042, 
Faculdade de Farmácia, Universidade Federal de Minas Gerais, Av. Presidente Antônio Carlos, 6627, 
Campus Pampulha, Belo Horizonte, Minas Gerais, CEP 31270-901, Brazil. Email: 
leomarie@gmail.com 
cPrograma Interunidades de Pós Graduação em Bioinformática. Instituto de Ciências Biológicas, 
Bloco K, Sala 163, Campus Pampulha, Belo Horizonte, Minas Gerais, CEP 31270-901, Brazil. 
dHealth Economics and Financing Research, Health Systems & Population Studies Division, icddr, b,  
Dhaka, Bangladesh. Email: razzaque.sarker@gmail.com 
eDepartment of Management Science, University of Strathclyde, Glasgow, UK. Email:  
itamar.megiddo@strath.ac.uk; alec.morton@strath.ac.uk 
fThe Center for Disease Dynamics, Economics & Policy, 1400 Eye St NW, Suite 500, Washington, DC 
20005, USA.  
gDepartment of Pharmacoepidemiology, Institute of Pharmacy and Biomedical Sciences. 161 
Cathedral Street, Glasgow G4 0RE, United Kingdom. Email: Brian.Godman@strath.ac.uk; 
marion.bennie@strath.ac.uk; samantha.alvarez-madrazo@strath.ac.uk 
hDivision of Clinical Pharmacology, Karolinska Institute, Karolinska University Hospital, SE-141 86, 
Stockholm, Sweden. Email: Brian.Godman@ki.se  
iHealth Economics Centre, Liverpool University Management School, Liverpool, UK. Email: 
Brian.Godman@liverpool.ac.uk 
jSchool of Pharmacy, Department of Public Health and Pharmacy Management, Sefako Health 
Sciences University, Pretoria, South Africa 
kFarr Institute of Health Informatics Research, University of Strathclyde, Institute of Pharmacy and 
Biomedical Sciences, 161 Cathedral Street, Glasgow G4 0RE, United Kingdom.  
 
*Author for correspondence: Brian Godman, Strathclyde Institute of Pharmacy and Biomedical 
Sciences, University of Strathclyde, Glasgow G4 0RE, United Kingdom. Email:  
brian.godman@strath.ac.uk. Telephone: 0141 548 3825. Fax: 0141 552 2562 and Division of Clinical 
Pharmacology, Karolinska Institute, Karolinska University Hospital Huddinge, SE-141 86, Stockholm, 
Sweden. Email: Brian.Godman@ki.se. Telephone + 46 8 58581068. Fax + 46 8 59581070 
 
(Accepted for publication in Expert Review of Vaccines – Please keep Confidential) 
 
Abstract  
Introduction: Dengue is a serious global health problem endemic in Brazil. Consequently, our aim was 
to measure the costs and disease burden of symptomatic dengue infections in Brazil from the 
perspective of the Brazilian Public Health System (SUS) between 2000 and 2015 using Brazilian 
public health system databases. Specific age group incidence estimates were used to calculate the 
disability-adjusted life years (DALYs) to gain a better understanding of the disease burden. Areas 
covered: SUS spent almost USD159 million and USD10 million to treat dengue and severe dengue, 
respectively, between 2000-2015. This is principally hospitalization costs with the majority of patients 
self-treated at home with minor symptoms. The average notification rate for dengue was 273 per 
100,000 inhabitants and 3 per 100,000 for severe dengue, with annual DALYs estimates ranging 
between 72.35 to 6,824.45 during the 16 years. Expert commentary: The epidemiological and 
morbidity burden associated with dengue is substantial in Brazil, with costs affected by the fact that 
most patients self-treat at home with these costs not included in SUS. The Brazilian government 
urgently needs to proactively evaluate the real costs and clinical benefits of any potential dengue 
vaccination program by the National Immunization Program to guide future decision making. 
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1. Introduction 
 
Dengue virus (DENV) is a serious threat to public health, with an estimated of 3.97 billion people at 
risk worldwide [1,2]. It is caused by four distinct strains of Flavivirus (DENV1-4) and is transmitted by 
mosquitos of the Aedes genus. The global estimates of the prevalence of dengue vary with 
approximately 50 to 200 million dengue infections annually, with 500,000 cases of severe dengue and 
over 20,000 deaths annually [3,4]. As a result, DENV is currently considered the most important 
vector-borne infection in several endemic countries. Most of the at-risk population live in tropical and 
subtropical regions, where conditions are favorable for mosquitos with the Americas, South-East Asia, 
and the Western Pacific regions the most seriously affected [5-12].  
 
Dengue is a major public health problem in Brazil and is endemic in all regions of the country, with 
mandatory notification to the Brazilian Notifiable Diseases Information System (SINAN). SINAN was 
started in 1990, and the system was introduced countrywide in 1994 to collect and process individual 
notification forms and the follow-up of cases (three levels: municipality, state and federal government) 
[13-16]. According to SINAN, approximately 9.5 million dengue cases were notified between 2000 and 
2015 in Brazil, with the number of notified cases increasing from approximately 696,000 in 2002 to 
1.68 million cases in 2015 [17-19]. Recognizing the challenges of dengue, the Brazilian Ministry of 
Health developed the National Dengue Control Program in early 2002 with its main objectives being 
the reduction of infestation by Aedes aegypti, the incidence of dengue, and deaths due to severe 
cases [20].  
 
The majority of individuals with dengue in Brazil self-treat at home because the symptoms usually last 
between two and seven days and are not severe enough to access SUS services [21]. However, 
some patients can develop severe symptoms that necessitate hospitalization services. These include 
leukopenia (reduction in white blood cells, hemorrhage (bleeding) and circulatory collapse (shock) 
associated with deaths [22]. Currently, there is no specific antiviral treatment to manage the dengue 
virus [23-26]. At the end of 2015, the Brazilian Government approved the first dengue vaccine (CYD-
TDV; Dengvaxia®) to prevent DENV infection with a reported global efficacy of 60%, recommended 
for individuals between 9 and 45 years old [27,28].  
 
Several studies have estimated the economic [4,29-34] and disease burden of dengue in endemic 
countries including Brazil [35-38]. However, economic analyses of the impact of dengue in Brazil have 
included only a few cities, e.g. Goiania, Belo Horizonte, Rio de Janeiro, Teresina, Recife and Belem 
[34], or a low number of individuals (n=550) [29]. Moreover, these publications did not include all the 
available dengue registers that are currently used in the Brazilian Public Health System (Sistema 
Único de Saúde - SUS) services. i.e. the Hospitalization Information System (SIH/SUS). Within SUS, 
healthcare services including medicines are provided free of charge to patients who meet the agreed 
criteria. We believe it is essential to include these data alongside assessing disease burden through 
measures such as disability-adjusted life years (DALYs) to fully understand the economic and disease 
burden of dengue in Brazil, as recommended by Brazilian Ministry of Health [39, 40]. DALYs are 
typically used to measure the burden of disease and have been verified to evaluate the burden of 
dengue in endemic countries [41, 42]. They are a composite measure of years of life lost (YLL) and 
the years lived with disability (YLD) [41], and represent one lost year of "healthy" life. The sum of 
DALYs for a disease can measure the gap between the current health status and an ideal health 
situation [43]. 
 
Researching issues of the current economic and disease burden of dengue within a public healthcare 
system is a crucial first step before assessing the potential role and value of new health technologies 
to prevent or treat the disease. This includes funding decisions for new vaccines alongside funding 
existing prevention programmes. We have already undertaken a willingness to pay study for the 
dengue vaccine in Brazil, and we believe this analysis will add to this information when the authorities 
in Brazil and other countries assess new technologies for dengue [9]. 
 
Consequently, the objective of this study is to measure the costs and disease burden of symptomatic 
DENV infections in Brazil from the SUS (national health) perspective. We believe this is the first study 
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to fully evaluate the hospitalization and other SUS services involved in Brazil considering the reported 
frequency and costs with this arbovirus based on all the dengue registers over the past 16 years.    
 
As a result, we believe this comprehensive approach can contribute to future discussions on the 
development of public policies to control dengue infection in Brazil and other endemic countries. This 
includes deliberations regarding the funding of new treatment approaches at requested prices.   
 
2. Patients and Methods 
 
2.1 Study Design and Population 
We conducted a descriptive study involved different Brazilian Health Databases to demonstrate the 
epidemiological, morbidity and economic impact of dengue in an important endemic country. Brazil is 
a tropical country, localized in the South America with more than 200 million inhabitants, and has 26 
states and the Federal District distributed in five regions (North, Northeast, South, Southeast and 
Midwest). According to the National Survey of Domicile conducted by Brazilian Institute of Geography 
and Statistics (IBGE), in 2013, the highest share of residents in the country is located in the Southeast 
region with 42% of the population, followed by the Northeast.  84% of the inhabitants live in urban 
areas. The mean income per capita was US$315.97 (1128.00BRL) in 2014 [44]. The country‘s public 
health system, named SUS, was established in 1988 by a constitutional decree in order to guarantee 
access to health care to the entire population. SUS maintains primary and outpatient centers, 
hospitals, diagnostic laboratories and provides access to pharmaceuticals including vaccines. There 
are a several SUS databases pertaining to different sectors of the health system such as the 
Ambulatory Information System (SIA/SUS), Hospitalization Information System (SIH/SUS) and 
Mortality Information System (SIM/SUS) [15, 16, 21]. 
 
This study assessed the profile of services and procedures performed for the treatment of dengue 
and severe dengue throughout Brazil between January 2000 and December 2015 from the SUS 
perspective, i.e. the public healthcare system perspective. During the study period, it was possible to 
see that the dengue epidemics, in different years, involved the four serotypes [45]. Our study included 
all registers associated with dengue and severe dengue in the country obtained from the different 
SUS databases such as SINAN, SIH/SUS and SIM/SUS yielding, respectively, notification as well as 
hospitalization cases and deaths (2000-2015). As mentioned, dengue is a mandatory notification 
disease in Brazil, in other words, all new cases of this infection need to be registered in the SINAN 
database, which is a specific SUS Database associated with mandatory notification of diseases [16]. 
However, only the severe cases generally consume hospital services, with the majority of patients 
undergoing self-treated at home which are not covered by SUS; consequently, the extent of their 
utilization and costs are not recorded in the SUS databases [22].  
 
The data used were extracted through the deterministic-probabilistic link involving various SUS 
administrative databases, i.e. the Hospital Information System (SIH) and the Mortality Information 
System (SIM) [46-49]. The data derived from these systems were used to obtain epidemiological 
parameters and expenditures with the disease in Brazil. In addition, the Mortality Information System 
(SIM/SUS) was used to record deaths due to dengue occurring between January 2000 and December 
2015. 
 
Until 2014, the common serious dengue manifestation, which has the presence of bleeding and other 
severe symptoms, was denoted as dengue hemorrhagic fever; thereafter, this was changed to severe 
dengue. Both denominations were coded with the same ICD: A91. In our study, we collected all 
registers with ICD-10 A90 and A91 using SUS databases (SIH/SUS) and dates involving dengue 
hemorrhagic fever (until 2014) and severe dengue (after 2014) to estimate the dengue notification 
incidence.   
 
It is important to highlight that SINAN (notification), SIH (hospitalization) and SIM (mortality) are 
completely independent SUS databases. The analyses were conducted using the R Software [50] and 
Microsoft Excel 2010.   
 
2.2 Profile of dengue cases in Brazil 
We estimated the median incidence of dengue for each year based on all registers of notification and 
hospitalization cases for dengue and severe dengue between 2000 and 2015. Since dengue is an 
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infection associated with four serotypes an individual can be infected more than one time in the same 
year, which can result in more than one notification (register applied for a symptomatic case) or 
hospitalization case (SIH/SUS) for each individual. We considered the number of new cases 
registered, obtained by SINAN and SIH/SUS in the country divided by the national population, and 
expressed this per 100 thousand inhabitants to calculate the dengue incidence for each context 
(notification and hospitalization), in line with information provided by the Ministry of Health [15, 20]. 
The number of new cases was obtained from the SINAN database [16-19]. The number of new 
hospitalization cases were obtained from the SIH/SUS database, extracted through the deterministic-
probabilistic link. In this scenario, we included all individuals who had dengue (SUS code: 74500457, 
74300440, 0303010010) and severe dengue (SUS code: 74300628, 74500627, 0303010029) 
registered in the SUS databases. We assessed the distribution of dengue and severe dengue cases 
in Brazil considering the total number of patients on the hospitalization registers in terms of their 
gender, region and age (in years) groups, involving children, adolescents and adults, which is similar 
to other studies [43, 51].  
 
The mortality was assessed from the number of deaths associated with ICD-A90 (dengue) and A91 
(severe dengue). After this, we evaluated mortality by age, year, and location. 
 
2.3 Costs of treatment 
In order to better understand the costs incurred for this infection in the country, all records of 
procedures performed in the country associated with the treatment of dengue (Procedures: 
74300440, 74500457, 0303010010; ICD-10: A90) and severe dengue were analyzed. In addition, all 
associated procedures (Supplementary Material) presented in Dengue Guidelines of the Ministry of 
Health [12] as these services for the treatment of dengue are covered by SUS. All death registries 
were also interrogated in order to better understand the full impact of dengue in Brazil from a SUS 
perspective. We did not include any costs associated with self-treatment at home as these are not 
covered by SUS. 
 
All procedures and costs were obtained via the Hospital Information System (SIH) from 2000 until 
2015. We included procedures utilized until 90 days after dengue or severe dengue was registered in 
the SUS database. The list of procedures selected and associated with dengue or severe dengue 
were included in the Supplementary Material (TS1). These procedures are associated with clinical 
activities, examinations or complications applied to dengue and severe dengue in accordance with the 
Dengue Guideline [12]. These costs in the database for dengue and severe dengue were converted 
to US dollars according to World Bank (2017: USD 1 = 3.191 BRL) for comparative purposes.  
 
2.4 Burden of disease (DALY) 
We also estimated the disability-adjusted life years (DALYs) to measure the burden of dengue. We 
calculated DALY using the equations below, considering the discount rate [42].   
 
 
) 
 
Where: N = number of deaths; L (YLL) = standard life expectancy at age of death in year; I: number of 
incident cases; DW = disability weight; r = discount rate; L (YLD)= duration of disability (years). 
 
 
Since the numbers of hospitalizations represent most of the dengue cases and deaths in Brazil, we 
assessed the burden using data on hospitalization. We calculated the DALYs for 17 age groups in 5-
year increments (<5 years old to >80 years old), similar to a previously published study for 
comparative purposes [30]. We obtained the number of dengue and severe dengue cases and deaths 
for each age group from the profile of this infection in Brazil through the Hospitalization Databases 
(SIH/SUS) per year. We used disability weights of 0.051 and 0.133 for dengue and severe dengue, 
respectively, in accordance with the Global Burden of Disease Study 2015 [52]. Life expectancy 
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expectations were taken from World Health Organization life tables [53]. In addition, according to the 
Ministry of Health in Brazil, the mean duration of hospital stay for dengue and severe dengue in Brazil 
is currently three and five days, respectively [54].  
 
A discount rate of 5% was used to estimate the burden of disease as indicated by the Brazilian 
Ministry of Health [39, 40]. The parameters involved in this evaluation were presented in 
Supplementary Material (Table S3).  
 
2.5 Ethics  
This study was approved by the Ethics Committee of Federal University of Minas Gerais (COEP) 
under the CAAE 57219816.0.0000.5149. 
 
3. Results 
 
3.1 Dengue Profile in Brazil (2000-2015) 
 
A total of 702,270 individuals with dengue, and 29,925 with severe dengue, used SUS services 
between 2000 and 2015, and 739,177 hospitalization procedures were verified as dengue and severe 
dengue. Table 1 provides the characteristics of the population associated with dengue and severe 
dengue in Brazil between 2000 and 2015. The majority of verified cases were among females: 
53.69% dengue cases and 52.15% severe dengue cases. Individuals between 5 and 44 years 
represented 68.04% and 72.14% of dengue and severe dengue cases respectively.  
 
2.3% of individuals had more than one dengue episode in the same year. This was especially 
common in the Northeast. Reported rates of dengue and severe dengue varied by region, as shown 
in Figure 1A. The Northeast and Southeast had the highest number of cases; combined, they 
accounted for over 66% of dengue cases across the country. The South had the lowest number of 
cases at almost 2% of cases. The highest number of cases occurred in 2002, 2008, 2010, and 2013, 
when epidemics occurred (Figure 1B).  
 
Table 1: Characteristics of Population: Profile of Dengue and Severe Dengue in Brazil 2000-2015 
 
Variable Dengue Severe Dengue 
N° individuals (n) 702,270 29,925 
Gender (%)   
Men 45.77 47.31 
Female 53.69 52.15 
NA 0.54 0.54 
Frequency per 
age group (years-
old) (%) 
  
< 1 1.37 2.53 
1-4 4.24 5.66 
5-14 17.64 31.02 
15-24 20.38 15.30 
25-34 16.91 14.30 
35-44 13.11 11.52 
45-54 10.40 8.87 
55-64 7.49 5.42 
65-74  4.96 3.25 
75-84 2.68 1.69 
≥ 85 0.82 0.44 
Had dengue more 
than one time in 
the same year 
(%) 
0.93 1.38 
  NB: NA = Not available    
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Figure 1: Distribution of Dengue cases by region and year in Brazil (2000-2015) 
 
 
Figure 2 shows the dengue disease burden by age group. The highest percentage of cases occurred 
in age groups 5 to 14 years old (dengue: 17.6% and severe dengue: 31.0%) and 15 to 24 years old 
(dengue: 20.4% and severe dengue: 15.3%). In other words, the number of dengue cases and deaths 
were highest among children, adolescents and young adults among the age groups 15 to 24 (dengue 
cases: 20.38%; death: 15.42%).  Adults and elderly people between 45 and 84 years old represented 
27.8% of the recorded deaths.    
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Figure 2: Distribution of Dengue, Severe Dengue and Deaths per age in Brazil 
 
 
3.2 Dengue and Severe Dengue profile and incidence in Brazil  
The number of registered dengue and severe dengue cases, combining ambulatory care and 
hospitalization, are reported in Table 2. The number of hospitalizations observed between 2000 and 
2015 are shown in Figure 3. The median incidence of notifications and hospitalizations were 273 
cases/100,000 and 3 cases/100,000 inhabitants respectively. The respective incidence of severe 
dengue were 25 cases/100,000 inhabitants and 1 case/100,000 inhabitants verified from SUS 
Hospitalization Information System Database. 
  
Disease incidence, hospitalizations, and deaths where highest in the years when there was an 
epidemic, i.e. 2002, 2008, 2010, 2013, as demonstrated in Table 2.  
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Table 2: Epidemiological burden of dengue and severe dengue in Brazil (2000-2015) by SUS 
perspective 
 
 
*SINAN Databases [17, 18]. Note: Dengue is an infectious disease associated with four serotypes (DENV1-4) 
and Brazil is an endemic country where an individual can be infected more than once, which can result in more 
than one hospitalization case (SIH/SUS) for each individual.     
 
Figure 3: Hospitalization cases and dengue deaths per year in Brazil (2000-2015) 
 
 
3.3 Costs of dengue and severe dengue in Brazil 
Tables 3 and 4 document the costs of dengue and severe dengue among hospitalized patients from a 
SUS perspective.  
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Table 3: Summary of hospitalization costs (USD) and deaths associated with dengue and severe 
dengue in Brazil and regions (2000-2015) 
 
 
 
Table 4: Economic Impact (USD) associated with Dengue and Severe Dengue in Brazil by SUS 
perspective (2000-2015) 
 
 
 
The estimated total global direct medical costs of dengue and severe dengue for the Brazilian public 
healthcare system (SUS) were USD159.5 million and USD 11.3 million, respectively, during the 16 
years (2000-2015). The treatment costs with dengue and severe dengue associated with the 
Southeast and Northeast represented almost 21.0% (USD76 million) and 48% (USD 32 million) of the 
total costs across the country during this period, demonstrating differences within the regions of 
Brazil.  
 
Among the estimated costs, approximately, USD 604,000 was spent on dengue clinical complications 
(e.g. chronic pulmonary disease, fluid and electrolyte disorders) during the 16 years (2000-2015) (TS2 
Supplementary Material). The cost breakdowns are shown in detail in Table 4.      
 
3.4 Burden of disease (DALY) 
Table 5 provides estimates of the disease burden by year based on patients accessing SUS services 
for dengue and severe dengue. The estimated DALYs were highest in epidemic periods, i.e. 2002 
(1824.40), 2008 (6625.18), 2010 (6824.45), 2013 (5872.27) and 2015 (4155.96), which results in a 
higher relative weight of adults compared children.  
 
Table 5: Estimated DALYs by year in Brazil (2000-2015) 
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4. Discussion 
 
We believe our study is the first study that has comprehensively evaluated the economic and health 
burden of dengue in an endemic country from a public health perspective, accounting for all dengue 
and severe dengue in Brazil from 2000 to 2015. This is different from previous publications that were 
conducted involving only some regions of Brazil [33, 38], utilized interviews [34, 55, 56], one city [57] 
and in some regions of a South American country [34, 58]. Marteli and collaborators (2015) also 
estimated the economic burden of dengue in Brazil ranging from USD 371 million (2009) to USD 1228 
million (2013). However, the authors used the dengue notification registers from SINAN (Sep/2012 to 
Oct/2013) to estimate the burden [33] and not just the SUS costs, and their analysis was only based 
on 6 cities. As a result, there is likely to be an appreciable over-estimation of the actual costs from a 
public healthcare (SUS) perspective. This was the case. In our study, between 2000 and 2015, there 
were a total of 9,599,678 (dengue: 98%; severe dengue: 2%) and 739,177 hospitalization cases 
(dengue: 95.9%; severe dengue: 4.1%) generating a total cost of USD159.5 million dengue and 
USD10.2 million for severe dengue through SUS services during the study period. Our findings are 
similar to a study conducted in the Philippines for dengue in terms of the profile of dengue and its 
impact on hospitalization [59].  
 
Our study demonstrated a median incidence of dengue and severe dengue of 273 and 3 cases per 
100,000 inhabitants, respectively, and a low hospitalization incidence of 25 (dengue) and 1 (severe 
dengue) case per 100,000 inhabitants between 2000 and 2015. The high number of cases 
documented in the national databases in 2002, 2008, 2010, 2013 and 2015, reflect the epidemics 
registered in these years in Brazil [17,18]. Regarding the profile of dengue cases, of the 9,599,678 
[17] cases notified for this infection in Brazil between 2000 and 2015, only 7.7% (739,177) used SUS 
services. This confirms previous studies that the majority of dengue patients self-treat at home and 
did not receive ambulatory care or hospitalization services. This may well explain the relatively low 
observed costs over the 16 years despite high prevalence rates compared for instance with the study 
of Marteli et al [33].  In addition, the number of recorded dengue cases may be an under-estimate if 
the vast majority of patients are self-treated despite compulsory notification. However, using real 
world data involving hospitalization services within SUS (epidemiology and cost), together with other 
economic analysis [60, 61], appreciably contributes to discussions involving the possible incorporation 
of any new dengue vaccine into the Brazilian National Immunization Program at requested prices 
alongside other measures to control the virus and its symptoms. 
 
Our study demonstrated considerable variation in cases, with high occurrence of dengue in the 
Northeast and Southeast regions of Brazil, similar to the findings of Teixeira and collaborators [36]. 
This is also similar to the findings of the National Survey by Household in 2013 whereby the 
Southeast (18.2%) and Northeast (48.0%) regions contributed most of the dengue cases in Brazil [44, 
62]. The southeast region is the most populated region in the country [44, 62], and the accelerated 
and disorganized urbanization in some States helps to understand the burden of dengue in these 
areas [63, 64]. In the Northeast region, the lack of adequate sanitation is more frequent compared 
with the Southeast, which could also help explain the higher prevalence there [62].  
 
With respect to calculating the economic burden of dengue, encouragingly, our study was able to 
capture all dengue services in SUS Databases across the country, adding robustness to our findings. 
Recent publications have applied an expansion factor where all municipalities have not been 
incorporated into the analysis. In the Philippines, the authors adjusted the reported number of 
clinically diagnosed dengue cases using an expansion factor of 7.0 and estimated an annual average 
of 842,867 cases with direct medical costs (in 2012 US dollars) of USD 345 million during 2008-2012 
[59]. They estimated the aggregate direct medical cost considering a scenario where all clinical cases 
consumed public financial resources. In our study, typically SUS only spent financial resources on 
patients who had severe symptoms rather than milder cases, with these self-paid. This aspect could 
have influenced the higher costs in the Philippines compared to our findings.  
 
Shepard et al (2014) conducted an economic and epidemiological study in India between 2006 and 
2012, which projected 5,778,406 annual dengue cases in the country (national expansion factor: 282). 
They calculated that the direct medical costs were USD 548 million per annum with this infection 
considering the number of cases adjusted with the expansion factor, different again to our study [59]. 
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The aggregate cost of hospitalization associated with dengue compared to ambulatory care costs 
were higher in Cambodia [30] and India [37], similar to our results.  
 
Regarding the morbidity associated with dengue, in Mexico, dengue hospitalization cases 
represented only 29.2 (2010) and 27.2 (2011) DALYs. This compares with our findings of 3372 to 
6496 since 2007 (Table 5). This is similar though to other studies evaluating DALYs in Brazil [38]. 
However, other countries such as Cambodia had a higher burden of dengue in 2006 at 5,603 DALYs 
and 2007 at 16,330 DALYs [30]. This shows the value at looking at metrics such as DALYs when 
developing public health policies.  
 
Along with considering funding new technologies to treat dengue, it is important to highlight the costs 
the Brazilian government already invests every year to help prevent dengue, chikungunya and zika 
virus, which are associated with the same vector [65, 66]. These costs would continue even with 
increasing eradication of dengue with effective vaccination and other programs. In 2014, the Brazilian 
government authorized the transfer of the Health Surveillance Component of R$150.0 million BRL 
(US$ 45.05 million), which corresponds to 12% of the annual fixed health surveillance budget, for 
activities to prevent and control the arboviruses [67]. Potential prices paid for such a vaccine also 
have to be evaluated against patients’ willingness to pay for such a vaccine [60]. In addition, from the 
National Dengue Profile obtained via SUS databases, we did not find any register associating the 
seroprevalence with each one of the procedures registered (ambulatory and hospitalization). 
Considering that the first dengue vaccine approved in the country (Dengvaxia®) has a different 
efficacy for each serotype [28], it could be important to evaluate the dengue seroprevalence in the 
country. In this context, it is important to develop a National Seroprevalence Study for dengue to 
better inform future policy decision making if this does not already exist.   
 
We acknowledge that there are limitations with our study. We did not include costs such as costs per 
night and cost per inpatient stay, because they were not available in the SUS databases. However, all 
available clinical procedures (registers and costs) associated with dengue and severe dengue 
treatment within SUS were included in our calculations. We also did not include ambulatory care costs 
and costs associated with patients who typically manage their condition at home as this data is not 
captured within the available SUS datasets. As a result, the direct medical costs reported by us are 
likely to be an under-estimate. We also did not consider the sub-notification cases as our principal 
objective was to estimate the costs involved with the registers for dengue in the country according to 
the SUS databases (SIA/SIH/SUS). Another limitation of this study involved the absence of the 
economic assessment of the dengue notification scenario. Additionally in our study, we did not include 
indirect costs as we adopted the perspective of SUS. We are aware other studies have demonstrated 
the important contribution of these costs for dengue [29, 38, 55, 57, 58].   
 
We also used the discount rate of the of the Brazilian Ministry of Health to calculate the burden of the 
infection [39, 40] which is different from that applied in  Global Burden of Disease (GDB) [52]. Despite 
these limitations, we believe that we have provided reliable data for SUS based on the direct medical 
costs under its jurisdiction and the current epidemiological impact of dengue in Brazil. 
 
5. Conclusion 
 
Our study demonstrated the high costs and epidemiological context in Brazil from the SUS 
perspective associated with dengue over the past 16 years from 2000 to 2015. The challenge to 
eliminate the arboviruses in Brazil needs to continue and there needs to be investment and 
implementation of a national program with continuous and rigorous monitoring of the  
presence of the vector in all municipalities throughout Brazil and not only some cities. If the country 
had success in the past to eradicate this vector, it would be important to implement and invest efforts 
to conduct activities and repeat the satisfactory result of eradicating Aedes aegypti. 
 
The potential incorporation of any vaccine for dengue needs to be carefully examined within the 
Brazilian context as prevention programmes are ongoing and there are also considerable demands 
on available resources.  In this context, and given the current economic situation, there is an urgent 
need for a robust cost-effectiveness analysis of any new dengue vaccine or treatment of the infection 
to guide future purchasing decisions. These are considerations for the future.  
 
12 
 
 
6. Key Issues 
 A total of 702,270 and 29,925 individuals utilized SUS services to treat, respectively, dengue and 
severe dengue in Brazil, totalizing 739,177 hospitalizations and 4986 deaths associated with this 
infection in the country, between January 2000 and December 2015. This resulted in almost 
USD159 million and USD10 million spent by SUS to treat dengue and severe dengue, 
respectively, between January 2000 and December 2015. 
 Annual DALYs estimates ranging between 42.64 to 6,824.45 over the study period associated 
with DENV in Brazil. 
 The use of real world numbers involving the hospitalization services within the Brazilian public 
health system (epidemiology and cost) combined with other economic analysis can contribute to 
discussions involving the possible incorporation of a dengue vaccine into the Brazilian National 
Immunization Program. 
 The Brazilian government urgently needs to proactively evaluate the real costs and clinical 
benefits of any potential dengue vaccination program by the National Immunization Program to 
guide future decision making. 
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